11865 views | 1 decade ago
At Illumina, we work on game-changing technologies that benefit human health. Our work contributes to important questions like: "Why is a person more likely to develop Type-2 diabetes?" or "Why do some...
2338 views | 1 decade ago
Illumina Cancer Webinar Series: Gad Getz, Ph.D., founder of the Cancer Genome Computational Analysis group at the Broad Institute and Director of Bioinformatics at the Mass General Cancer Center and...
705 views | 1 decade ago
Mark Van Oene, Vice President of Global Sales at Illumina, discusses the company's development of market-specific products and solutions for cancer and genetic disease.
523 views | 1 decade ago
Luis Diaz, MD, Associate Professor of Oncology at Ludwig Center for Cancer Genetics and Therapeutics at Johns Hopkins, discusses the application of genomic information in a clinical manner.
1367 views | 1 decade ago
Christopher Mason, Assistant Professor in the Department of Physiology and Biomedicine at the Weill Cornell Medical College, describes how tumor evolution can be tracked by sequencing the transcriptome,...
504 views | 1 decade ago
Jennifer Stone, Ph.D., Cancer Genomics Market Manager at Illumina, discusses Illumina's view of cancer research and how by continually advancing its technologies it is supporting researchers with tools...
8545 views | 1 decade ago
Kenneth Bloom, MD, FCAP, Chief Medical Officer at Clarient (GE Healthcare), discusses the practical aspects of how next-generation sequencing will be applied in the clinical laboratory.
878 views | 1 decade ago
Jeffrey Miller, Ph.D., CSO and CEO of Invivoscribe, discusses the clinical basis for clonality testing, current technologies to identify clonality and the development of new assays to identify and monitor...